Keywords
Uveitis
Vasculitis
Treatment
Categories
How to Cite
Abstract
Introduction: Behcet’s disease is a systemic disorder linked to occlusive vasculitis and of a relatively unknown pathogenesis. Ocular manifestations of the disease mainly comprise uveitis in 60-80% of cases, followed by retinal vasculitis and then retinal vein occlusion. The aim of this study is to analyze ocular manifestations of patients with confirmed Behcet’s disease, their complications, treatment and evolution in our tertiary care unit of Morocco.
Patients and methods : It is a retrospective study of patients with confirmed Behcet along with ocular manifestations, hospitalized in the department of ophthalmology at the teaching hospital of Rabat from Juin 2002 to June 2012.
Results: A total of 133 patients were included in the study, being 29,5 years-old on average. Visual acuity is very low before treatment: 56% had less than 1/10. Ocular manifestations included mainly uveitis with 89.96%, followed by retinal vasculitis 73.6% and maculopathy 22%. The percentage of the eyes of which the VA was inferior to 1/10 became 35.9% after the treatment.
Conclusion: The most frequent clinical presentation in our context is a total uveitis with a posterior predominance associated with a vasculitis. Pupillary seclusion is the most frequent complication. Corticotherapy and immunosuppressive drugs are the therapeutic methods used the most in our context.
References
H Behçet. [Uber rezidivierende aphthose durch ein virus verursachte geschwure am mund, am auge und an den genitalien]. Dermatol Wochenschr.1937; 105:1152–63.
Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Gonçalves O, et al. Behçet's disease–a contemporary review. J Autoimmun. May- Jun 2009; 32(3-4):178-88. https://doi.org/10.1016/j.jaut.2009.02.011
Pleyer U, Hazirolan D, Winterhalter S, Stübiger N. [Behçet's disease-ophthalmological and general aspects part I: etiology, pathogenesis and diagnostics]. Ophthalmologe. 2012; 109(11):1129-41. https://doi.org/10.1007/s00347-012-2780-z
Paovic J, Paovic P, Sredovic V. Behcet’s Disease: Systemic and Ocular Manifestations. BioMed R Int. 2013; 2013:247345. https://doi.org/10.1155/2013/247345
International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014 Mar; 28(3): 338-47. https://doi.org/10.1111/jdv.12107
Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990 May 5; 335(8697):1078-80. https://doi.org/10.1016/0140-6736(90)92643-V
Durrani K, Ahmed M, Foster CS. Adamantiades-Behcet disease: diagnosis and current concepts in management of ocular manifestations. Compre Ophthalmol update. Jul-Aug 2007; 8(4):225-33.
Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behçet’s disease: an international collaborative study. Br J Ophthalmol. 2007 Dec; 91(12):1579-82. http://dx.doi.org/10.1136/bjo.2007.123554
Hajji Z, Berraho A. Œil et maladie de Behçet. EMC Ophtalmologie. 2003;21-225-C-20. [Accessed 26th May 2021]. Available from: https://www.em-consulte.com/article/18434/oeil-et-maladie-de-behcet
I. Ksiaa, N. Abroug , M. Kechida , S. Zina , B. Jelliti , S. Khochtali Et al . [The eye and Behcet's disease]. J Fr Ophtalmol. April 2019; 42(4):133 -146. https://doi.org/10.1016/j.jfo.2019.02.002
Stubiger N, Pleyer U. [Typical and atypical ocular manifestations of Behcet's disease]. Ophthalmologe. 2012 Jun; 109(6):558-62. https://doi.org/10.1007/s00347-012-2587-y
Paovic J, Paovic P, Sredovic V. Correlation between Ocular Manifestations and Their Complications as Opposed to Visual Acuity and Treatment in Behcet's Disease. Autoimmune Dis. 2013; 2013: 842673. https://doi.org/10.1155/2013/842673
Davatchi F, Shahram F, Chams C, Nadji HCA. Behcet’s disease. Acta Medica Iranica. 2005; 43(4): 233-242. [Accessed 26th May 2021]. Available From: https://acta.tums.ac.ir/index.php/acta/article/view/3001
Benamour S, Zeroual B, Bennis R, Amraoui A, Bettal S. [Behcet's disease. 316 cases]. Presse Med.1990 Oct 6; 19(32):1485-9.
Ghayad E, Tohme A. [Behcet disease in Lebanon]. Rev Rhum Ed Fr. 1994 Apr; 61(4):287-8.
Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol. 2004 Sep; 138(3):373-80. https://doi.org/10.1016/j.ajo.2004.03.022
Kone-Paut I. [Behcet's disease: pediatric features]. Ann Med Interne. 1999 Nov; 150(7):571-5.
Chiheb S, Chakib A, Lakhdar H. [Behcet's disease]. Ann Dermatol Venereol. Jun-Jul 2003; 130(6-7):657-63.
Janati K, EL Omari K, Benchiki H, Hamdani M, Lakhdar H. [Ocular manifestation of Behcet disease (study of 50 patients consulting in dermatology department)]. Rev Med Interne. 2005 Oct; 26(10):771-6. https://doi.org/10.1016/j.revmed.2005.06.015
Filali-Ansary N, Tazi-Mezalek Z, Mohattane A, Adnaoui M, Aouni M, Maaouni A, et al. [Behcet disease. 162 cases]. Ann Med interne (Paris). 1999 Apr; 150(3):178-88.
Zierhut M, Saal J, Pleyer U, Kotter I, Durk H, Fierlbeck G. Behcet's disease: epidemiology and eye manifestations in German and Mediterranian patients. Ger J Ophthalmol.1995 Jul; 4(4):246-51.
el Belhadji M, Hamdani M, Laouissi N, Zaghloul K, Amraoui A, Benamour S. [Ophthalmological involvement in Behcet disease. Apropos of 520 cases]. J Fr Ophtalmol. 1997; 20(8):592-8.
Hamza M, Meddeb S, Mili I, Ouertani A. [Bolus of cyclophosphamide and methylprednisolone in uveitis in Behcet's disease. Preliminary results with the use of new criteria of evaluation]. Ann Med Interne (Paris). 1992; 143(7):438-41.
Cochereau-Massin I, Wechsler B, Le Hoang P, Le Thi Huong D, Girard B, Rousselie F, et al. [Ocular prognosis in Behcet's disease]. J Fr Ophtalmol. 1992; 15(5):343-7.
Atmaca LS. Fundus changes associated with Behcet's disease. Graefes Arch Clin Exp Ophthalmol. 1989; 227(4):340-4. https://doi.org/10.1007/BF02169409
Daghfous MT, Ammar M, Kamoun M, Triki F. [Clinical aspects and course of Adamantiades-Behcet disease in Tunisia: a report on 41 cases (author's transl)]. J Fr Ophtalmol. 1980; 3(8-9):463-8.
Benchekroun O, Lahbil D, Lamari H, Rachid R, El Belhadji M, Laouissi N, et al. [Macular damage in Behcet's disease]. J Fr Ophtalmol. 2004 Feb; 27(2):154-9. https://doi.org/10.1016/S0181-5512(04)96110-4
Lamari H, Baha AT, Benhaddou M, Alikane O, Hamdani M, Zaghloul K, et al. [Involvement of the optic nerve in the course of Behcet's disease (presentation of 148 cases)]. Bull Soc Belge Ophtalmol. 2003(289):914.
Deuter CM, Zierhut M, Doycheva D, Kötter I. [Treatment of Behcet's disease yesterday and today]. Ophthalmologe. 2012; 109(6):568-74. https://doi.org/10.1007/s00347-011-2504-9
Kaklamani VG, Kaklamanis PG. Treatment of Behçet's disease—An update. Semin Arthritis Rheum. 2001 Apr; 30(5):299-312. https://doi.org/10.1053/sarh.2001.19819
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2014 Alami Fadoua et al.
